Versor Investments LP Purchases New Holdings in Thermo Fisher Scientific Inc. $TMO

Versor Investments LP acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 669 shares of the medical research company’s stock, valued at approximately $271,000.

Other hedge funds have also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares in the last quarter. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth about $31,000. IMA Advisory Services Inc. bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Finally, DiNuzzo Private Wealth Inc. raised its holdings in Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after buying an additional 61 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $566.47 on Friday. The business has a 50-day simple moving average of $516.99 and a two-hundred day simple moving average of $461.35. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The stock has a market cap of $212.83 billion, a price-to-earnings ratio of 32.73, a PEG ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same period in the prior year, the firm posted $5.28 EPS. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 17,104 shares of the company’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at $65,247,057.48. This represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the sale, the executive vice president directly owned 21,152 shares in the company, valued at $12,144,420.80. This trade represents a 1.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 36,420 shares of company stock worth $19,980,884. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. William Blair initiated coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. Barclays boosted their target price on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a report on Tuesday, October 28th. Nineteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.